Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Sinovac Included in Deloitte’s Technology Fast 50 China

publication date: Nov 3, 2008

Sinovac Biotech Ltd. said its main operating entity, Sinovac Beijing, was named to the Deloitte Technology Fast 50 China 2008. A vaccine maker, Sinovac’s revenues derive mainly from its hepatitis A vaccine, Healive™. The company also makes a combination hepatitis A & B vaccine, a flu vaccine and an avian flu vaccine. Sinovac said it was put on the list because of its 290% growth rate over the past three years. More details...

Stock Symbol: (AMEX: SVA)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital